NE-3107市場：市場規模、予測、新たな洞察-2032年

NE-3107は、炎症性ERKシグナルを選択的に阻害することで、神経炎症を抑制し、炎症に起因するインスリン抵抗性やその他の主要な病的炎症カスケードを抑制する経口投与の新規低分子化合物です。

最近完了したパーキンソン病治療薬NE3107の第I/II相臨床試験では良好な結果が得られており、パーキンソン病第II相臨床試験のデータが採択されたことから、2023年に開催されるアルツハイマー病とパーキンソン病に関する国際会議でこの結果を発表する予定です。BioVieはSUNRISE-1のピボタル第IIb相試験を2023年第3四半期に開始する予定であり、SUNRISE-2はピボタル第III相試験を2024年第1四半期後半に開始する可能性があります。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病態を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、NE-3107の優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品がNE-3107と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のNE-3107市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるNE-3107の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 NE-3107市場評価

• パーキンソン病におけるNE-3107の市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療薬NE-3107の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: NE-3107, Clinical Trial Description, 2023
• Table 2: NE-3107, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: NE-3107 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: NE-3107 Market Size in the US, in USD million (2019-2032)
• Table 7: NE-3107 Market Size in Germany, in USD million (2019-2032)
• Table 8: NE-3107 Market Size in France, in USD million (2019-2032)
• Table 9: NE-3107 Market Size in Italy, in USD million (2019-2032)
• Table 10: NE-3107 Market Size in Spain, in USD million (2019-2032)
• Table 11: NE-3107 Market Size in the UK, in USD million (2019-2032)
• Table 12: NE-3107 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: NE-3107 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: NE-3107 Market Size in the United States, USD million (2019-2032)
• Figure 3: NE-3107 Market Size in Germany, USD million (2019-2032)
• Figure 4: NE-3107 Market Size in France, USD million (2019-2032)
• Figure 5: NE-3107 Market Size in Italy, USD million (2019-2032)
• Figure 6: NE-3107 Market Size in Spain, USD million (2019-2032)
• Figure 7: NE-3107 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: NE-3107 Market Size in Japan, USD million (2019-2032)

"NE-3107 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about NE-3107 for Parkinson's disease in the seven major markets. A detailed picture of the NE-3107 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NE-3107 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NE-3107 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

NE-3107 is a novel orally administered small molecule that selectively inhibits the inflammatory ERK signaling and thereby reduces neuroinflammation, inhibit inflammation-driven insulin resistance, and other major pathological inflammatory cascades.

The recently completed Phase I/II trial of NE3107 for treating Parkinson's disease depicted positive results and the company will present these results at the International Conference on Alzheimer's and Parkinson's Diseases to be held in 2023 as the data from Phase II Parkinson's Disease trial is accepted for the presentation. BioVie plans to initiate the pivotal Phase IIb trial SUNRISE-1 in 3Q2023, and SUNRISE-2 is a potentially pivotal Phase III starting late 1Q2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the NE-3107 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on NE-3107 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NE-3107 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around NE-3107.
• The report contains forecasted sales of NE-3107 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for NE-3107 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NE-3107 Analytical Perspective by DelveInsight

• In-depth NE-3107 Market Assessment

This report provides a detailed market assessment of NE-3107 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• NE-3107 Clinical Assessment

The report provides the clinical trials information of NE-3107 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NE-3107 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to NE-3107 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NE-3107 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of NE-3107 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NE-3107 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of NE-3107?
• What is the clinical trial status of the study related to NE-3107 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NE-3107 development?
• What are the key designations that have been granted to NE-3107 for Parkinson's disease?
• What is the forecasted market scenario of NE-3107 for Parkinson's disease?
• What are the forecasted sales of NE-3107 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to NE-3107 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. NE-3107 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. NE-3107 Market Assessment

• 5.1. Market Outlook of NE-3107 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of NE-3107 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of NE-3107 in the United States for Parkinson's disease
  • 5.3.2. Market Size of NE-3107 in Germany for Parkinson's disease
  • 5.3.3. Market Size of NE-3107 in France for Parkinson's disease
  • 5.3.4. Market Size of NE-3107 in Italy for Parkinson's disease
  • 5.3.5. Market Size of NE-3107 in Spain for Parkinson's disease
  • 5.3.6. Market Size of NE-3107 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of NE-3107 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options